The purpose of the assessment is to examine the effectiveness and safety of the duodenal-jejunal bypass sleeve/EndoBarrier® in in adults aged 18 years or older with grade II or III obesity (with comorbidities) and/or type 2 diabetes mellitus (+ obesity ≥ grade I) who are not adequately controlled with medication (oral and/or insulin) and lifestyle intervention. This intervention is compared to either bariatric surgery and endoscopic techniques or anti-diabetes pharmacotherapy and lifestyle changes.
Final version of the assessment was published in July 2013
Below is the documentation provided by the Joint Assessment authoring team (the document includes the final project plan and the comments table as appendices):
Duodenal-jejunal Bypass Sleeve for treatment of obesity with or without Type II diabetes mellitus_Rapid REA_Final_Jul 2013